• 1
    Blasko JC, Grimm PD, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993; 3: 240249
  • 2
    Albert M, Tempany CM, Schultz D et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer 2003; 98: 949954
  • 3
    Talcott JA, Clark JA, Stark PC, Mitchell SP. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001; 166: 494499
  • 4
    Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995; 32: 465471
  • 5
    D'Amico AV, Cormack R, Tempany CM et al. Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1998; 42: 507515
  • 6
    Beard CJ, Propert KJ, Rieker PP et al. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. J Clin Oncol 1997; 15: 223229
  • 7
    Talcott JA, Rieker P, Clark JA et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998; 16: 275283
  • 8
    Talcott JA, Manola J, Clark JA et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21: 39793986
  • 9
    Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009; 27: 39163922
  • 10
    Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care 2001; 39: 11181130
  • 11
    Litwin M. Health-related quality of life after treatment for localized prostate cancer. Cancer 1995; 75: 20002003
  • 12
    Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899905
  • 13
    Crook J, Fleshner N, Roberts C, Pond G. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol 2008; 179: 141146
  • 14
    Litwin MS, Gore JL, Kwan L et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007; 109: 22392247
  • 15
    Victorson DE, Brucker PS, Bode RK et al. Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol 2013; doi: 10.1016/j.urolonc.2012.09.006 [Epub ahead of print]
  • 16
    Register SP, Kudchadker RJ, Levy LB et al. An MRI-based dose-reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. Brachytherapy 2013; 12: 210216
  • 17
    Talcott JA, Clark JA, Manola J, Mitchell SP. Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand. J Urol 2006; 176: 15581564
  • 18
    Greenfield S, Aronow HU, Elashoff RM, Watanabe D. Flaws in mortality data. The hazards of ignoring comorbid disease. JAMA 1988; 260: 22532255
  • 19
    D'Amico AV, Chen MH, Oh-Ung J et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 2002; 54: 436441
  • 20
    Cella D, Bullinger M, Scott C, Barofsky I. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc 2002; 77: 384392
  • 21
    Sloan JA, Cella D, Frost M, Guyatt GH, Sprangers M, Symonds T. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 2002; 77: 367370
  • 22
    Hewitt M, Simone JV eds. Ensuring Quality Cancer Care. Washington, DC: National Academy Press, 1999
  • 23
    Wu AW, Snyder C, Clancy CM, Steinwachs DM. Adding the patient perspective to comparative effectiveness research. Health Aff (Millwood) 2010; 29: 18631871
  • 24
    Arora NK, Reeve BB, Hays RD, Clauser SB, Oakley-Girvan I. Assessment of quality of cancer-related follow-up care from the cancer survivor's perspective. J Clin Oncol 2011; 29: 12801289
  • 25
    Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care 2009; 47: 826834
  • 26
    Fenton JJ, Jerant AF, Bertakis KD, Franks P. The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch Intern Med 2012; 172: 405411
  • 27
    Bogdanich W. At V.A. Hospital, a rogue cancer unit. New York Times, 21 June 2009
  • 28
    Bogdanich W. Radiation offers new cures, and ways to do harm. New York Times, 24 January 2010
  • 29
    Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 12501261
  • 30
    Potosky AL, Davis WW, Hoffman RM et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004; 96: 13581367
  • 31
    Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 1991; 114: 621628
  • 32
    Hessel AC, Moreno MA, Hanna EY et al. Compliance with quality assurance measures in patients treated for early oral tongue cancer. Cancer 2010; 116: 34083416
  • 33
    Desch CE, McNiff KK, Schneider EC et al. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol 2008; 26: 36313637
  • 34
    Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 2002; 94: 835844
  • 35
    Olivotto IA, Bajdik CD, Plenderleith IH et al. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 1994; 330: 805810
  • 36
    Hawn MT, Vick CC, Richman J et al. Surgical site infection prevention: time to move beyond the surgical care improvement program. Ann Surg 2011; 254: 494501
  • 37
    Anthony T, Murray BW, Sum-Ping JT et al. Evaluating an evidence-based bundle for preventing surgical site infection: a randomized trial. Arch Surg 2011; 146: 263269
  • 38
    Cella D, Riley W, Stone A et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol 2010; 63: 11791194